DICE Therapeutics

Dice Therapeutics is a biotechnology startup that focuses on developing innovative oral medicines for the treatment of chronic autoimmune and inflammatory diseases. The company's primary market is patients suffering from conditions such as psoriasis and other diseases mediated by the IL-17 cytokine, a type of protein that plays a crucial role in immune responses.

Dice Therapeutics operates in the healthcare and pharmaceutical industry, specifically within the immunology sector. The company's business model revolves around the development of its proprietary DELSCAPE platform. This platform is designed to identify selective oral small molecules that can modulate protein-protein interactions (PPIs) as effectively as systemic biologics. In simpler terms, Dice Therapeutics is working on creating oral medicines that can control the way proteins interact in our bodies, similar to how current biologic medicines work.

The current biologic medicines, while effective, are not ideally suited for chronic treatment due to their administration methods, which often involve injections or intravenous infusions, and require regular patient monitoring. Dice Therapeutics aims to overcome these challenges by developing oral medicines that are more convenient for patients.

The company generates revenue through the development and commercialization of its therapeutic candidates. Once a drug is successfully developed, it can be patented and sold to healthcare providers or directly to patients.

Keywords: Biotechnology, Oral Medicines, Autoimmune Diseases, Inflammatory Diseases, IL-17 Cytokine, DELSCAPE Platform, Protein-Protein Interactions, Small Molecules, Drug Development, Chronic Treatment.